DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD.

Position in GILD — Gilead Sciences, Inc.

CIK 1672142 Singapore, U0

Back to GILD Full portfolio

Position in GILD

as of Jun 30, 2026 · filed Jul 23, 2026 Compact

Position Value

$10,107,200

+$5,926,100 QoQ

Shares Held

80,000

+166.7% QoQ

Ownership

0.006%

of shares outstanding

% of Portfolio

1.67%

of 13F equity value

Holder Rank

#429

of 2,266 holders

Holding Since

Jun 2025

4 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Common Shares in GILD Over Time

Shares Held

Position Value (USD)

Derivatives in GILD

reported options exposure · as of Sep 30, 2025

CallValue

$2,775,000

CallShares

25,000

PutValue

$2,775,000

PutShares

25,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. holds $30,306,066 across 7 Drug Manufacturers - General names. GILD ranks #1 (33.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	GILD	Gilead Sciences, Inc. This page	80,000	$10,107,200
2	AZN	Astrazeneca PLC	30,000	$5,688,600
3	JNJ	Johnson & Johnson	18,300	$4,647,651
4	MRK	Merck & Co., Inc.	31,173	$4,005,730
5	NVS	Novartis AG	16,800	$2,632,896
6	LLY	ELI LILLY & Co	1,500	$1,799,145
7	SNY	Sanofi	33,400	$1,424,844

All Filings in GILD

Export CSV

5 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$10,107,200	80,000	+166.7%	Shares	Defined	2026-07-23
2026-03-31	$4,181,100	30,000	+66.7%	Shares	Defined	2026-05-14
2025-09-30	$2,775,000	25,000	—	Call	Sole	2025-11-13
2025-09-30	$2,775,000	25,000	—	Put	Sole	2025-11-13
2025-06-30	$1,995,660	18,000	—	Shares	Defined	2025-08-14
No filing history on record for this holder in this stock.